Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval

Hagop M. Kantarjian, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalReview article

39 Scopus citations


Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.

Original languageEnglish (US)
Pages (from-to)530-533
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number5
StatePublished - Oct 1 2013
Externally publishedYes



  • CML
  • Homoharringtonine (HHT)
  • Omacetaxine mepesuccinate
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this